

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of
JAYNES et al

Serial No. 10/753,339

Filed: January 9, 2004

For: HUMAN IMMUNODEFICIENCY VIRUS VACCINE

Atty. Ref.: 1579-880

TC/A.U.: 1648

Examiner: Stucker, J.J.

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

TERMINAL DISCLAIMER

Your petitioner, DUKE UNIVERSITY, a corporation having an office and place of business at Durham, North Carolina 27708-0083 and BETH ISRAEL DEACONESS MEDICAL CENTER, a corporation having an office and place of business at 330 Brookline Avenue, Boston, Massachusetts 02215 represents that they are the assignees as recorded in an assignment at Reel 011684/Frame 0117 (Duke University) and in an assignment at Reel 014230/Frame 0875 (Beth Israel), of all right, title and interest in and to Application Serial No. 10/753,339, filed January 9, 2004, for HUMAN IMMUNODEFICIENCY VIRUS VACCINE.

Your petitioner hereby disclaims the terminal part of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term as presently shortened by any terminal disclaimer of any patent issuing

from Application Serial No. 10/973,475 and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to such patent granted on the above-identified application shall be the same as the legal title to any patent issuing from Application Serial No. 10/973,475, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors or assigns.

Petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term as presently shortened by any terminal disclaimer of any patent issuing from Application Serial No. 10/973,475 in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

The evidentiary documents accompanying this document or referred to above have been reviewed by the undersigned and it is certified that to the best of the assignee's knowledge and belief, title is in the assignee seeking to take action.

Check either box 1 or 2 below, as appropriate.

1. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.

2. The undersigned is an attorney or agent of record.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

DUKE UNIVERSITY

By: 
Name: Robert L. Taber
Title: Vice Chancellor, Corporate and
Venture Development
Date: July , 2005

**BETH ISRAEL DEACONESS
MEDICAL CENTER**

By: _____
Name:
Title:
Date: _____

Terminal disclaimer fee under 37 C.F.R. § 1.20(d) included. If missing, the Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.